AngioDynamics AI Stock Analysis
Want to see ANGO full AI Analyst Report?
AngioDynamics (ANGO) AI Stock Analysis
AngioDynamics
(NASDAQ:ANGO)
ANGO scores as middling overall: financial performance is improving (revenue rebound, solid gross margin, modestly positive cash flow and a debt-free balance sheet) but the company remains loss-making and equity has trended down. Technical indicators are notably weak with the stock below key moving averages and depressed momentum readings, while valuation is difficult to assess due to a negative P/E and no dividend yield data. The latest earnings call supports the recovery narrative with maintained guidance and better profitability metrics, but continued adjusted-loss guidance and reimbursement/tariff uncertainty temper the outlook.
AngioDynamics (ANGO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $499.19M
- Dividend Yield
- ―
- Average Volume (3M)
- 639.60K
- Price to Earnings (P/E)
- -15.0
- Beta (1Y)
- 0.14
- Revenue Growth
- 8.20%
- EPS Growth
- -0.88%
- Country
- US
- Employees
- 632
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
AngioDynamics Business Overview & Revenue Model
Company Description
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as periph...
How the Company Makes Money
AngioDynamics makes money primarily by selling medical devices to hospitals, outpatient centers, and other healthcare providers, with revenue generally recognized from product sales (typically upon delivery/transfer of control depending on contract t...
AngioDynamics Earnings Call Summary
The call had a strongly positive tone, supported by 6.9% total revenue growth, 13.2% MedTech growth, sustained double-digit Auryon growth, strong AlphaVac and NanoKnife performance, improved profitability, a debt-free balance sheet, and maintained fiscal-year guidance. The principal challenges were the year-over-year AngioVac decline, sequential NanoKnife disposable seasonality, cash usage in Q1, tariff and inflation-related margin factors, an ongoing adjusted loss outlook, and the need for broader NanoKnife reimbursement. Highlights significantly outweighed the lowlights.
Q1-2027 Updates
Positive Updates
Negative Updates
Company Guidance
For fiscal 27, AngioDynamics continues to anticipate net sales of $336 million to $341 million, representing growth of between 5% to 6.5% over 2020 revenue of $320.2 million; MedTech net sales are expected to grow 12% to 15% year over year and MedDevice sales to be roughly flat, while gross margin is expected to be in the range of 54% to 55%, adjusted EBITDA in the range of $13 million to $16 million, and adjusted loss per share in the range of $0.29 to $0.24. The company remains on track to generate positive cash flow from operations for the full fiscal year, is targeting approximately 10% of sales for R&D going forward, expects mechanical thrombectomy to continue to grow with AngioVac in the single digit growth and AlphaVac driving that growth, and expects the impact from tariffs to be broadly similar to fiscal 26 based on its current view of the tariff situation, but this remains dynamic and clearly subject to change.
AngioDynamics Financial Statement Overview
Summary
Mixed fundamentals: TTM revenue rebounded sharply and gross margin is solid (~54.6%), with operating cash flow and free cash flow turning modestly positive. However, profitability remains negative (TTM net margin ~-11.5%; EBIT margin ~-11.2%), and equity has declined over time despite a debt-free balance sheet.
Income Statement
38NegativeBalance Sheet
72PositiveCash Flow
46Neutral| Breakdown | TTM | May 2026 | May 2025 | May 2024 | May 2023 | May 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 325.38M | 320.17M | 292.50M | 303.91M | 338.75M | 316.22M |
| Gross Profit | 181.07M | 174.89M | 157.71M | 154.70M | 174.25M | 165.73M |
| EBITDA | -9.87M | 488.00K | 1.74M | -6.13M | 12.19M | 11.13M |
| Net Income | -32.94M | -36.74M | -33.99M | -184.35M | -52.44M | -26.55M |
Balance Sheet | ||||||
| Total Assets | 241.93M | 267.16M | 280.14M | 317.67M | 532.64M | 552.75M |
| Cash, Cash Equivalents and Short-Term Investments | 33.97M | 53.86M | 55.89M | 76.06M | 44.62M | 28.82M |
| Total Debt | 10.74M | 0 | 10.15M | 4.73M | 64.58M | 33.78M |
| Total Liabilities | 77.97M | 96.34M | 97.17M | 112.08M | 154.34M | 128.26M |
| Stockholders Equity | 163.96M | 170.82M | 182.97M | 205.59M | 378.30M | 424.49M |
Cash Flow | ||||||
| Free Cash Flow | 1.44M | 508.00K | -14.59M | -33.93M | -4.27M | -11.49M |
| Operating Cash Flow | 3.67M | 3.09M | -10.13M | -28.16M | 78.00K | -7.19M |
| Investing Cash Flow | -7.55M | -5.95M | -10.18M | 123.72M | -9.75M | -19.31M |
| Financing Cash Flow | -954.00K | 564.00K | -255.00K | -64.25M | 25.42M | 7.68M |
AngioDynamics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANGO, the sentiment is Negative. The current price of 11.87 is below the 20-day moving average (MA) of 12.01, below the 50-day MA of 13.42, and below the 200-day MA of 12.55, indicating a bearish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 42.95 is Neutral, neither overbought nor oversold. The STOCH value of 47.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANGO.
AngioDynamics Risk Analysis
AngioDynamics disclosed 34 risk factors in its most recent earnings report. AngioDynamics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAngioDynamics Peers Comparison
Overall Rating
ISRG84Outperform
LMAT75Outperform
MMSI71Outperform
ICUI64Neutral
TFX57Neutral- ANGO52Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ISRG | 84Outperform | $153.77B | 53.00 | 17.03% | ― | 20.45% | 8.75% |
| LMAT | 75Outperform | $1.79B | 28.06 | 15.33% | 1.21% | 11.83% | 17.64% |
| MMSI | 71Outperform | $5.19B | 32.20 | 9.65% | ― | 9.34% | 33.77% |
| ICUI | 64Neutral | $4.48B | 74.39 | 2.81% | ― | -5.82% | ― |
| TFX | 57Neutral | $6.15B | 18.64 | 9.74% | 0.88% | -29.30% | ― |
| ANGO | 52Neutral | $499.19M | -15.03 | -19.25% | ― | 8.20% | -0.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ANGO | Angiodynamics, Inc. | 11.87 | -0.04 | -0.34% | |
| ICUI | ICU Medical | 179.27 | 44.75 | 33.27% | |
| ISRG | Intuitive Surgical | 443.59 | -103.12 | -18.86% | |
| LMAT | Lemaitre Vascular | 78.29 | -7.83 | -9.09% | |
| MMSI | Merit Medical | 86.63 | 0.84 | 0.98% | |
| TFX | Teleflex | 155.10 | 52.06 | 50.53% |
AngioDynamics Corporate Events
AngioDynamics Names New CEO Amid Leadership Transition
PositiveOn October 2, 2026, AngioDynamics’ board appointed industry veteran Eric Honroth as President and CEO and a director, effective November 2, 2026, succeeding long-time chief executive Jim Clemmer, who will retire on that date after leading the company...
AngioDynamics Delivers Q1 2027 Growth, Confirms Outlook
PositiveFor the fiscal first quarter of 2027, ended August 31, 2026, AngioDynamics reported net sales of $80.9 million, up 6.9% year on year, with Med Tech revenue rising 13.2% to $39.9 million and Med Device sales edging up 1.4% to $41.0 million. GAAP gross...
AngioDynamics posts record Q4 and fiscal 2026 results
PositiveAngioDynamics reported record financial results for its fiscal fourth quarter and full year ended May 31, 2026, highlighting a seventh consecutive quarter of double-digit Med Tech growth and positive adjusted EBITDA. Pro forma net sales rose 8.0% in...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 09, 2026